Talking Euretina

Couldn't be in every room at Euretina 2026? In the last of our highlights series, hear from Dr Caroline Baumal, Dr Sarah Touhami and Prof Francesco Boscia as they talk about how AI is changing geographic atrophy care, whether the retina could flag heart disease that angiograms miss, and why signs of diabetic retinal disease may appear sooner than we thought.

When is it time to stop treating radiation maculopathy? Dr Lara Sandri (Johannesburg) and Dr Rodrigo Anguita (Moorfields Eye Hospital, London) share their highlights from the Euretina Congress in Vienna, from a five-phase model of radiation damage and the genetics that separate uveal from skin melanoma, to predicting proliferative vitreoretinopathy before it takes hold and how regulators will judge AI. The sessions are available to watch on demand.

Can a macular hole close without a gas bubble? Dr Stratos Gotzaridis and Dr Elise Philippakis share their highlights from Euretina 2026 in Vienna: a buckle placed without sutures, the unresolved debate over myopic traction maculopathy, and why myopia is no longer just a retina problem.

Ask ten surgeons which tamponade to use in retinal detachment repair and you will get ten different answers. Ahead of his Ingrid Kreissig Lecture at the Euretina Congress in Vienna, Prof. David Steel joins Prof. Jens Kiilgaard to ask why the evidence base is still so thin, what our gases really cost the environment, and why he believes a revolution in tamponades is coming.

Ahead of his Ophthalmologica Lecture at the Euretina Congress in Vienna, Dr. Elon van Dijk joins Ophthalmologica Editor-in-Chief Prof. Martin Zinkernagel to explain why central serous chorioretinopathy remains so hard to pin down — and what multimodal imaging can tell us about which eyes will resolve on their own. They discuss the evidence behind half-dose PDT, the trials that got us there, and the career choices behind the lecture

Ahead of her Gisbert Richard Lecture at the Euretina Congress in Vienna, Prof. Noemi Lois tells Prof. Nicole Eter why diabetic tractional retinal detachment is far more than a mechanical problem — and why we may be catching patients too late. They discuss the scarce evidence on risk factors, anti-VEGF before vitrectomy, tamponade choices, and what the EMERALD study means for clinic capacity

Ahead of his EURETINA Lecture in Vienna — "The Dark Side of the Moon: New Horizons in Dry AMD" — Past President Prof. Frank Holz joins President Prof. Nicole Eter for a wide-ranging conversation on his career, from pioneering retinal imaging to restoring central vision in advanced AMD, and why dry AMD may finally be at a turning point. Catch the lecture live in Vienna on Thursday 1 October

In tertiary practice, masquerades account for around 5% of uveitis cases — and missing one can cost sight, or life. Prof Bahram Bodaghi is joined by Prof Elisabetta Miserocchi and Prof Isabelle Audo on vitreoretinal lymphoma, the limits of diagnostic vitrectomy, IL-10:IL-6 ratios and MYD88, the paraneoplastic retinopathies CAR, MAR and BDUMP, and the inherited retinal diseases that quietly mimic inflammation. Essential listening before reaching for steroids

The Euretina Innovation Spotlight returns to Vienna on 30 September, bringing clinicians, industry, investors and regulators around one table. Prof. Anat Loewenstein, Prof. Nicole Eter and Dr. Kourous Rezaei tell Jonathan McCrea why innovation in retina is moving faster than ever, what the return of the EMA's Jane Mosley means for bridging Europe and the US, and why this exchange of ideas is something a traditional congress simply can't offer

Anti-VEGF has transformed how we treat retinopathy of prematurity — but at what long-term cost? Dr Kanmin Xue chairs a global discussion with Dr Domenico Lepore, Prof Wei-Chi Wu and Prof Andreas Stahl on injections versus laser, the RAINBOW and FIREFLEYE trial data, managing peripheral avascular retina, and why these babies may need follow-up for life. A frank look at the questions the evidence hasn't yet answered.